Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The neuronal acetylcholine receptor subunit alpha-6 (nAChRα6 or CHRNA6) is a subunit of nicotinic acetylcholine receptors (nAChRs), which are ligand-gated ion channels primarily found in the nervous system. It is expressed in dopamine-releasing neurons in midbrain regions and plays critical roles in modulating dopamine release, reward-related behaviors, motor function, and addiction. Variants and altered function of CHRNA6 have been associated with nicotine dependence, alcohol dependence, cocaine dependence, bipolar disorder, dystonia, and Parkinson’s disease. Drugs targeting α6-containing nAChRs are being explored for treating addiction disorders and neurodegenerative diseases.
Agonist binding to the receptor leading to conformational change and opening of the ion channel; Antagonist binding blocking the receptor and preventing activation.
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Neuronal Acetylcholine Receptor Subunit Alpha-6 (nAChRα6).